News
-
A farewell message from our CEO
An opportunity presents itself whenever a year ends to reflect on all that has been achieved. For ACTA, it has been a very big year…
-
ACTA welcomes inquiry findings into the approval processes for new drugs and novel medical technologies in Australia
With the aim of delivering better health for all Australians, the report from the Parliamentary inquiry into the approval processes for new drugs and novel…
-
Successful 2021 ACTA ASM
We sincerely thank everyone who was involved in making the 2021 ACTA ASM a huge success. Across the 3 days we had over 390 delegates…
Search News
General search and filters
Filter by:
Topics
Results filtered by:
-
A farewell message from our CEO
-
New MRFF Strategy and Priorities released
-
ACTA welcomes inquiry findings into the approval processes for new drugs and novel medical technologies in Australia
-
Inaugural Emerging Leader Investigator Awards
-
Successful 2021 ACTA ASM
-
Bringing together new and emerging CTNs
-
ACTA supports the White Coats Foundation – Power of One campaign
-
Consumer and Community Involvement in Clinical Trials webinar
-
CT:IQ Health Consumer Survey
-
Research Australia web consultation
-
ACSQHC – National One-Stop-Shop Survey
-
Clinical Trials – Phase 2 Advisory Committee Communique – Meeting 6, 1 October 2021